| pubmed-article:8527701 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8527701 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8527701 | lifeskim:mentions | umls-concept:C0037173 | lld:lifeskim |
| pubmed-article:8527701 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:8527701 | lifeskim:mentions | umls-concept:C0013295 | lld:lifeskim |
| pubmed-article:8527701 | lifeskim:mentions | umls-concept:C0034665 | lld:lifeskim |
| pubmed-article:8527701 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:8527701 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8527701 | lifeskim:mentions | umls-concept:C0378091 | lld:lifeskim |
| pubmed-article:8527701 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8527701 | pubmed:dateCreated | 1996-1-30 | lld:pubmed |
| pubmed-article:8527701 | pubmed:abstractText | Roxatidine acetate, a new H2 receptor antagonist, was compared with ranitidine in the treatment of duodenal ulcers in a double-blind multicentre study. Eighty-four patients with endoscopically proven duodenal ulcer were randomized to receive 150 mg roxatidine acetate or 300 mg ranitidine at bedtime. Repeat endoscopy was performed after 4 weeks (25-33 days) and if the ulcer had not healed, another endoscopy was performed after a further 4 weeks of treatment. Using per protocol analysis 73.6% of ulcers treated with roxatidine healed at 4 weeks compared to 72.2% of ulcers treated with ranitidine (P = NS). The healing rates at 8 weeks were 92% with roxatidine and 83.3% with ranitidine (P = NS). Using equivalence tests, the healing rate of roxatidine was found to be equivalent to that of ranitidine within a 20% region. Roxatidine users took significantly less antacids than ranitidine users (P < 0.05). There were no significant adverse effects due to roxatidine or ranitidine. Roxatidine is a safe effective drug in the treatment of duodenal ulcers with a healing rate comparable to that of ranitidine. | lld:pubmed |
| pubmed-article:8527701 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8527701 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8527701 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8527701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8527701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8527701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8527701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8527701 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8527701 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8527701 | pubmed:issn | 0815-9319 | lld:pubmed |
| pubmed-article:8527701 | pubmed:author | pubmed-author:LiuC KCK | lld:pubmed |
| pubmed-article:8527701 | pubmed:author | pubmed-author:KaneJ WJW | lld:pubmed |
| pubmed-article:8527701 | pubmed:author | pubmed-author:GELLP GPG | lld:pubmed |
| pubmed-article:8527701 | pubmed:author | pubmed-author:HoT KTK | lld:pubmed |
| pubmed-article:8527701 | pubmed:author | pubmed-author:NgH SHS | lld:pubmed |
| pubmed-article:8527701 | pubmed:author | pubmed-author:GweeK AKA | lld:pubmed |
| pubmed-article:8527701 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8527701 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:8527701 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8527701 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8527701 | pubmed:pagination | 379-82 | lld:pubmed |
| pubmed-article:8527701 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:meshHeading | pubmed-meshheading:8527701-... | lld:pubmed |
| pubmed-article:8527701 | pubmed:articleTitle | Roxatidine versus ranitidine in the treatment of duodenal ulcers: a randomized double-blind controlled multicentre study in Singapore. | lld:pubmed |
| pubmed-article:8527701 | pubmed:affiliation | Department of Medicine, Toa Payoh Hospital, Singapore. | lld:pubmed |
| pubmed-article:8527701 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8527701 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8527701 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8527701 | pubmed:publicationType | Multicenter Study | lld:pubmed |
